FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesWhy Brexit Happened and What to Do Next
Topic: Politics
TED Talk
Free
Commercialization of Personalized Medicines
Topic: Pharma Industry
Report
Members
COVID-19 and the Clinical Supply Chain: Mitigating Risk and Maintaining Business Continuity
Topics: COVID-19, Pharma Industry, Supply Chain
Position Paper
Free
